Stem Cell Clinic

Stem Cell Therapy – Genesis Medical Center

By Stem Cell Medical Center

In recent years, stem cells have proven to be a highly effective form of reparative medicine for a wide range of diseases. At Genesis Medical Center, we are proud to provide stem cell treatments. By utilizing this innovative technology, we harness the power of your own cells to repair damaged tissue, reduce inflammation, and improve blood flow. At Genesis Medical Center, we are dedicated to using the most up-to-date treatments to help our patients. Unendingly dedicated to your health and wellbeing, our caring team of doctors and specialist are here to help you feel better.

Stem Cell Therapy Can Help With Health Issues Including, But Not Limited To:

Where Do We Get The Stem Cells From?*

*We do not use embryonic stem cells

Find out more about all of our Stem Cell Therapy capabilities by clicking the button below.

Do not hesitate to get in touch with us today if you have any questions about stem cell therapy. A member of our compassionate team would be glad to hear from you. You can also request an appointment using the form to the right! During your free consultation, our team will give you an evaluation to determine whether you are a candidate for stem cell therapy.

Originally posted here:
Stem Cell Therapy - Genesis Medical Center

What Are The Similarities And Differences Between Embryonic …

By Adult Stem Cells

Human embryonic and adult stem cells each have advantages and disadvantages regarding potential use for cell-based regenerative therapies. Of course, adult and embryonic stem cells differ in the number and type of differentiated cells types they can become. Embryonic stem cells can become all cell types of the body because they are pluripotent. Adult stem cells are generally limited to differentiating into different cell types of their tissue of origin. However, some evidence suggests that adult stem cell plasticity may exist, increasing the number of cell types a given adult stem cell can become.

Large numbers of embryonic stem cells can be relatively easily grown in culture, while adult stem cells are rare in mature tissues and methods for expanding their numbers in cell culture have not yet been worked out. This is an important distinction, as large numbers of cells are needed for stem cell replacement therapies.

A potential advantage of using stem cells from an adult is that the patient's own cells could be expanded in culture and then reintroduced into the patient. The use of the patient's own adult stem cells would mean that the cells would not be rejected by the immune system. This represents a significant advantage as immune rejection is a difficult problem that can only be circumvented with immunosuppressive drugs.

Embryonic stem cells from a donor introduced into a patient could cause transplant rejection. However, whether the recipient would reject donor embryonic stem cells has not been determined in human experiments.

Go here to see the original:
What Are The Similarities And Differences Between Embryonic ...

Skeletal stem cells could regrow damaged bones

By Stem Cell Doctors

The breakthrough wasn't a simple affair. To pinpoint the human skeletal stem cell, the scientists couldn't just use the tricks they'd used to isolate the equivalent in mice. They had to compare the mouse's gene expression profiles with those of several human cell types you'd find on the growing ends of human bone. That let the group find cells with similar proteins as the mouse's skeletal stem cells, helping the team find relevant markers on human cells.

The findings will should help understand the nature of human bone, but Stanford noted that it's ultimately interested in medical uses. You could heal broken bones at a faster pace, repair cartilage or even grow new bones for reconstructive surgery. Conditions like arthritis and osteoporosis might be much less serious, as you could generate unaffected bones and cartilage as necessary. This is only the beginning, so any solutions are likely years away. Still, there could be a day when you don't have to worry as much about serious fractures or the effects of aging.

More here:
Skeletal stem cells could regrow damaged bones

Stem cells fill cancer scars | Stem Cell Worx News

By Stem Cell Doctors

27 March 2010

[Watch the video below from KABC-TV)

LOS ANGELES, Calif. (KABC).

When doctors perform cancer surgery, they often remove so much tissue that it leaves serious indentations altering a persons appearance.

If you saw Hersel Mikelians face now, youd never know he used to have a gaping hole on the right side of his face. I was very sad. I was very angry that the doctors previously, they did a surgery even though it was the right thing to do, said Mikelian.

He had a salivary gland cancer that required the removal of part of his jaw. I had a tremendous amount of pain in my jaw area because of the nerves, they were basically exposed, said Mikelian.

I looked for a reconstruction surgeon and most doctors did not want to touch me.

That is until he met cosmetic surgeon Dr. Nathan Newman. He pioneered a new treatment called the Stem Cell Lift. He removes fat from the patient and harvests one of the bodys most precious resource: adult stem cells.

He then doubles and triples the concentration of stem cells before injecting. The stem cell is what brings in the new blood vessels, rebuilds the structures, maintains the volume by replacing the fat cells that die off, said Newman. Not only can the fat and stem cells be used for cosmetic reasons, Newman says the stem cells are so smart they can also break up scaring caused by the cancer treatment and rebuild and reconstruct surrounding tissues. We take these fat cells that are enriched with stem cells and put them next to bone. I can actually grow bone and make that bone stronger and bigger, said Newman. He says theres no risk of rejection because youre using your own fat and stem cells.

It took about two years and about 20 to 24 injections. Mikelian says nobody can even tell he ever had a dent in his jaw and the nerves and tissues appeared to have healed. He has given me my face back. He has given me my confidence back. And he has given me my hope back, said Mikelian.

The price of the procedure depends on how many injections a person needs. The treatment of one area could run into the thousands. Newman says almost anyone can be a candidate for a Stem Cell Lift and the only limitation is that the procedure is dependent on how much fat a patient has.

This entry was posted on Saturday, March 27th, 2010 at 7:23 am and is filed under Stem Cell Worx. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.

See the original post:
Stem cells fill cancer scars | Stem Cell Worx News

Marion Ohio Stem Cell Therapy Doctor Scot Gray

By Stem Cell Doctors

Dr. Brandon Bupp is the doctor of chiropractic, owner/founder of Advanced Health and Wellness Center, and the owner/founder of Advanced Performance Crossfit and Fitness. Dr. Bupp suffered from headaches as a child which continued through high school until his dad took him to a chiropractor for an ankle injury. This visit changed his life and urged him to become a leading chiropractor.

He attended chiropractic school at the fountainhead of chiropractic, Palmer College of Chiropractic where chiropractic was founded. He was fortunate enough to train with the top chiropractors in the world. Dr. Bupp teamed up with Dr. John Kocka, M.D. and became medically integrated.

After learning the science and success of stem cell therapy, Dr. Bupp and his medical team knew he could reach an even wider range of people in pain, and expanded his practice. Stem cell therapy fits with Advanced Health and Wellness Centers belief in natural healing of the human body and focusing on your best health and wellness potential.

Stem cells divide and conquer to restore damaged tissue, ligaments, nerves, and cartilage, providing relief from chronic pain and other symptoms. Dr. Bupp and his medical team provide the best care and opportunities for patients in the Wadsworth, Ohio area to experience relief without resulting to surgery or medications.

Read the original here:
Marion Ohio Stem Cell Therapy Doctor Scot Gray

Induced Pluripotent Stem Cell Market to Reach US$ 2,299.5 …

By Induced Pluripotent Stem Cells

NEW YORK, May 31, 2018 /PRNewswire/

Ongoing Research to Make iPS Cell a Breakthrough Technology for Clinical Research

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

(Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research.jpg )

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Induced Pluripotent Stem Cell Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/induced-pluripotent-stem-cells-market.asp

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

Request Sample Report @ https://www.persistencemarketresearch.com/samples/17968

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the global induced pluripotent stem or iPS cell market is expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/market-research/induced-pluripotent-stem-cells-market/toc

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Get full Report Now https://www.persistencemarketresearch.com/checkout/17968

Persistence Market Research Overview

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact

Persistence Market Research

U.S. Sales Office:

305 Broadway, 7th Floor

New York City, NY 10007

+1-646-568-7751

United States

USA Canada Toll-Free: 800-961-0353

Email: sales@persistencemarketresearch.com

PMR Latest News: https://www.persistencemarketresearch.com/news

SOURCE Persistence Market Research Pvt. Ltd.

Excerpt from:
Induced Pluripotent Stem Cell Market to Reach US$ 2,299.5 ...

Use Of Induced Pluripotent Stem Cell Models To Elucidate …

By Induced Pluripotent Stem Cells

Degree Name

Doctor of Philosophy (PhD)

Cell & Molecular Biology

Jean Bennett

Choroideremia (CHM) is a rare monogenic, X-linked recessive inherited retinal degenerative disease caused by mutations in the Rab Escort Protein-1 (REP1) encoding CHM gene. CHM is characterized by childhood-onset night blindness (nyctalopia), progressive peripheral vision loss due to the degeneration of neural retina, RPE and choroid in a peripheral-to-central fashion. Most of CHM mutations are loss-of-function mutations leading to the complete lacking of REP1 protein. However, the primary retinal cell type leading to CHM and molecular mechanism remains unknown in addition to the fact of lacking proper disease models. In this study, we explored the utility of induced pluripotent stem cell-derived models of retinal pigment epithelium (iPSC-RPE) to study disease pathogenesis and a potential gene-based intervention in four different genetically distinct forms of CHM. A number of abnormal cell biologic, biochemical, and physiologic functions were identified in the CHM patient cells. Transduction efficiency testing using 11 recombinant adeno-associated virus (AAV) serotype 1-9, 7m8 and 8b showed a differential cell tropism on iPSC and iPSC-derived RPE. We identified AAV7m8 to be optimal for both delivering transgenes to iPSC-RPEs as well as to appropriate target cells (RPE cells and rod photoreceptors) in the primate retina. To establish the proof of concept of AAV7m8 mediated CHM gene therapy, we developed a AAV7m8.hCHM viral vector, which delivers the human CHM cDNA under control of CMV-enhanced chicken -actin promoter (CA). Delivery of AAV7m8.CMV.CA.hCHM to CHM iPSC-RPEs restored protein prenylation, trafficking and phagocytosis defects. The results confirm that AAV-mediated delivery of the REP1-encoding gene can rescue defects in CHM iPSC-RPE regardless of the type of disease-causing mutation. The results also extend our understanding of mechanisms involved in the pathophysiology of choroideremia.

Duong, Thu Thi, "Use Of Induced Pluripotent Stem Cell Models To Elucidate Retinal Disease Pathogenesis And To Develop Gene-Based Therapies" (2018). Publicly Accessible Penn Dissertations. 3003. https://repository.upenn.edu/edissertations/3003

Files over 3MB may be slow to open. For best results, right-click and select "save as..."

See the original post here:
Use Of Induced Pluripotent Stem Cell Models To Elucidate ...

Human Embryonic Stem Cells in Development, Volume 129 …

By Embryonic Stem Cells

Dr. Brivanlou received his doctoral degree in 1990 from the University of California, Berkeley. He joined Rockefeller in 1994 as assistant professor after postdoctoral work in Douglas Meltons lab at Harvard University. Among his many awards are the Irma T. Hirschl/ Monique Weill-Caulier Trusts Career Scientist Award, the Searle Scholar Award, the James A. Shannon Directors Award from the NIH and the Presidential Early Career Award for Scientists and Engineers. The Brivanlou laboratory has demonstrated that the TGF- pathway plays a central role in inductive interactions leading to the establishment of different neural fates, which begins by the specification of the brain. In studies of frog embryos, Dr. Brivanlou has made several influential discoveries, including the finding that all embryonic cells will develop into nerve cells unless they receive signals directing them toward another fate. A concept, coined the default model of neural induction, postulates that neural fate determination requires the inhibition of an inhibitory signal. His laboratory has contributed to the molecular and biochemical understanding of the TGF- signaling pathway and cross talk with other signaling networks, using comparative studies of frog and mouse embryos and mammalian cell culture. To address whether the default model of neural induction is conserved from amphibians to mammals (and humans in particular), Dr. Brivanlous laboratory was among the first to work directly in hESCs. Dr. Brivanlou and colleagues derived several hESC lines, called RUES1, 2 and 3 (Rockefeller University Embryonic Stem Cell Lines 1, 2 and 3). The RUES lines were among the first 13 hESC lines approved for use in research funded by the National Institutes of Health (NIH), under the NIH Guidelines for Human Stem Cell Research adopted in July 2009 under the Obama administration. Their current work focuses on the molecular dissection of the defining properties of ESCs their capacity for self-renewal and their ability to differentiate into a range of cell types. Dr. Brivanlous overall goal is to use hESCs to study early human embryonic development. Several collaborations with Rockefeller University physics laboratories have provided new insight, from the use of quantum dots for in vivo embryonic imaging (with Albert J. Libchaber) to development of new statistical tools for DNA microarray and high throughput proteomic analysis. Ongoing collaboration with Rockefellers Eric D. Siggia focuses on using a high throughput microfluidic platform to program hESC differentiation toward specific fates by dynamic changes of the signaling landscape and without compromising genetic integrity. Thus, the first steps of stem cell differentiation are being scrutinized using new high-resolution techniques drawn from physics. This data will be organized and developed into a predictive tool to rationally reprogram specialized fates from hESCs.

Go here to read the rest:
Human Embryonic Stem Cells in Development, Volume 129 ...

Reprogrammed stem cells identical to embryonic stem cells

By Embryonic Stem Cells

Click on photo (at left) to enlarge Photo:iPS cells feature reprogrammed stem cells: Credit: Moscow Institute of Physics and Technology

Russian researchers have concluded that reprogramming does not create differences between reprogrammed and embryonic stem cells.

Stem cells are specialized,undifferentiated cellsthat can divide and have the remarkable potential to develop into many different cell types in the body during early life and growth. They serve as a sort of internal repair system in many tissues, dividing essentially without limit to replenish other cells. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another more specialized cell type, such as a muscle cell, a red blood cell, or a brain cell. Scientists

distinguish several types ofstem cellspluripotent stem cells can potentially produce any cell in the body. No pluripotent stem cells exist in an adult body, rather they are found naturally in early embryos.

There are two ways to harvest pluripotent stem cells. The first is to extract them from the excess embryos produced duringinvitro fertilization procedures, although this practice is still ethically and technically controversial because it does destroy an embryo that could have been implanted. For this reason, researchers came up with the second way to get pluripotent stem cells reprogramming adult cells.

Reprogramming, the process of turning on genes that are active in a stem cell and turning off genes that are responsible for cell specialization was pioneered by Shinya Yamanaka, who showed that the introduction of four specific proteins essential during early embryonic development could be used to convert adult cells intopluripotent cells. Yamanaka was awarded the 2012 Nobel Prize along with Sir John Gurdon for the discovery that mature stem cells can be reprogrammed to become pluripotent.

Production of iPS cells: Isolate cells from patient; grow in a dish Treat cells with reprogramming Wait a few weeks Pluripotent stem cells Change culture conditions to stimulate cells to differentiate into a variety of cell types blood cells | gut cells | cardio muscle cells Credit: Moscow Institute of Physics and Technology

Thanks to their unique regenerative abilities, stem cells offer potential for treating any disease. For example, there have been cases of transplanting retinal pigment epithelium and spine cells from stem cells. Another experiment showed that stem cells were able to regenerate teeth in mice. Reprogramming holds great potential for new medical applications, since reprogrammed pluripotent stem cells (or induced pluripotent stem cells) can be made from a patients own cells instead of using pluripotent cells from embryos.

However, the extent of the similarity between induced pluripotent stem cells and humanembryonic stem cellsremains unclear. Recent studies highlighted significant differences between these two types of stem cells, although only a limited number of cell lines of different origins were analyzed.

Researchers compared induced pluripotent stem cell (iPSC) lines reprogrammed from adult cell types that were previously differentiated from embryonic stem cells. All these cells were isogenic, meaning they all had the same gene set.

Scientists analyzed the transcriptome the set of all products encoded, synthesized and used in a cell. Moreover, they elicited methylated DNA areas, because methylation plays a critical role in cell specialization. Comprehensive studies of changes in the gene activity regulation mechanism showed similarities between reprogrammed and embryonic stem cells. In addition, researchers produced a list of the activity of 275 key genes that can present reprogramming results.

Researchers studied three types of adult cells fibroblasts, retinal pigment epithelium andneural cells, all of which consist of the same gene set; but a chemical modification (e.g. methylation) combined with other changes determines which part of DNA will be used for product synthesis.

Scientists concluded that the type of adult cells that were reprogrammed and the process of reprogramming did not leave any marks. Differences between cells that did occur were thought to be the result of random factors.

We defined the best induced pluripotent stem cells line concept, says Dmitry Ischenko, MIPT Ph.D. and Institute of Physical Chemical Medicine researcher.

The minimum number of iPSC clones that would be enough for at least one to be similar to embryonic pluripotent cells with 95 percent confidence is five.

Clearly, no one is going to convert embryonic stem cells into neurons and reprogram them into induced stem cells. Such a process would be too time-consuming and expensive. This experiment simulated the reprogramming of a patientsadult cellsinto inducedpluripotent stem cellsfor further medical use, and even though the reprogramming paper, published in the journal Cell Cycle, does not currently propose a method of organ growth in vitro, it is an important step in the right direction. Both induced pluripotent cells and embryonic stem cells can help researchers understand how specialized cells develop from pluripotent cells. In the future, they may also provide an unlimited supply of replacement cells and tissues that can benefit many patients with diseases that are currently untreatable.

The study, titled, An integrative analysis of reprogramming in human isogenic system identified a clone selection criterion, concluded that reprogramming does not create differences between reprogrammed and embryonic stem cells, involved researchers from the Vavilov Institute of General Genetics, Research Institute of Physical Chemical Medicine, and the Moscow Institute of Physics and Technology (MIPT).

###

Read more:
Reprogrammed stem cells identical to embryonic stem cells

Embryonic Stem Cell Protocols by Kursad Turksen | Waterstones

By Embryonic Stem Cells

Now in two volumes, this completely updated and expanded edition of Embryonic Stem Cells: Methods and Protocols provides a diverse collection of readily reproducible cellular and molecular protocols for the manipulation of nonhuman embryonic stem cells. Volume two, Embryonic Stem Cell Protocols: Differentiation Models, Second Edition, covers state-of-the-art methods for deriving many types of differentiating cells from ES cells. The first volume, Embryonic Stem Cell Protocols: Isolation and Characterization, Second Edition, provides a diverse collection of readily reproducible cellular and molecular protocols for the isolation, maintenance, and characterization of embryonic stem cells. Together, the two volumes illuminate for both novices and experts our current understanding of the biology of embryonic stem cells and their utility in normal tissue homeostasis and regenerative medicine applications.

Publisher: Humana Press Inc. ISBN: 9781617377778 Number of pages: 456 Weight: 700 g Dimensions: 229 x 152 x 27 mm Edition: Softcover reprint of hardcover 2nd ed. 2006

"...elegantly introduces tremendous methods and protocols in ES studies...one of the most useful books that I have ever read in this field..." -Cell Biology International

"...highly valuable for any scientist who wants to make a start in the exciting field but also for experienced ES cell researchers who want to widen their repertoire" -Diabetologia

"...a very informative resource for any developmental or cell biologist with an interest in developments and prospects of ES cell research" -Molecular Biotechnology

"...a useful companion volume to other more specialized ES cell books..." -Nature Cell Biology

Read the original:
Embryonic Stem Cell Protocols by Kursad Turksen | Waterstones

→←